Clinical Implementation of Routine Screening for Fetal Trisomies in the UK NHS: Cell-Free DNA Test Contingent on Results From First-Trimester Combined Test

    loading  Checking for direct PDF access through Ovid


Abstracted from Ultrasound Obstet Gynecol 2016;47:45–52

Although detection of trisomies 21, 18, and 13 by cell-free DNA (cfDNA) analysis of maternal blood is superior to other methods of screening, it is expensive. To maximize performance at reduced cost, a strategy that can be used is to offer cfDNA testing contingent on the results of the first-trimester combined test that is used currently.

Related Topics

    loading  Loading Related Articles